Hyperglycaemia in pregnancy (HIP) is the umbrella term for conditions including gestational diabetes mellitus, type 2 and type 1 diabetes in pregnancy. Every year, about 21 million women worldwide experience HIP, but too few are diagnosed. HIP during pregnancy can lead to problems for both the foetus (malformations, increased mortality, weight gain) and mother (hypertension, infections, obstructed labour and bleeding). It also increases the risk of both mother and child developing type 2 diabetes later in life.
Studies have shown that universal HIP screening and treatment, including lifestyle interventions for type 2 diabetes prevention after delivery, is highly cost effective, even in lowincome countries. The WDF funds projects improving prevention, screening and treatment of HIP, and advocates for the wide adoption of international guidelines for diagnosis, management and care of HIP.